March 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference was an opportunity to discuss the role of NICE in a changing health and social care landscape in the context of the pandemic.
Delegates also examined proposals in the NICE Strategy 2021 to 2026: Dynamic, Collaborative, Excellent, which sets out a vision and priorities for transformation to keep pace with the development of integrated care, innovative treatments, and data-driven research and technology.
It also came with the NICE board agreeing changes to appraisals for technology and highly specialised medicines aimed at improving collaboration, flexibility and patient access to innovation.
Overall, the agenda brought out latest thinking on:
- the way forward - what is needed to deliver the ambitions set out in the NICE Strategy 2021 to 2026
- responsiveness - adapting recommendations and developing evidence-based guidelines in an evolving health and care landscape
- evaluation - speed, safety and efficiency, engagement with industry, and support for development and adoption of innovative medicines and health technology
- data - priorities for its use, and its role in developing guidance
- patients - centring on needs, and support for access to innovation including the role of managed access and funding
We are very pleased to have been able to include an opening keynote session with Sharmila Nebhrajani, Chairman, NICE, as well as contributions from Dr Paul Chrisp, Director, Centre for Guidelines, NICE and Helen Knight, Programme Director, Centre for Health Technology Evaluation, NICE.
There were also keynote contributions from: Dr Ben Goldacre, Lead, Goldacre Review; and Director, The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; Paul Naish, Head of UK Policy, AstraZeneca; Luella Trickett, Director, Value and Access, Association of British Healthcare Industries; David Thomas, Head of Policy for Access and Innovation, Alzheimer’s Research UK; and Professor Matt Westmore, Chief Executive, Health Research Authority.
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DHSC; DWP; the MHRA; the Office for Life Sciences; BEIS; DCMS; DIT; The Scottish Government; and the Welsh Government - as well as parliamentary pass-holders from the House of Commons.
